Infections with non-tuberculous mycobacteria and HIV;Nicht-tuberkulöse mykobakteriosen bei der HIV-infektion

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 23, 2010, Pages 1192-1197

  Herzmann, C ^a   Lange, C ^a  

^a Forschungszentrum Borstel ^*  (Norway)

Author keywords

AIDS; HIV infection; Immune reconstitution inflammatory syndrome (IRIS); Mycobacterium avium complex; Non tuberculous mycobacteria (NTM)

Indexed keywords

AMIKACIN; ANTIRETROVIRUS AGENT; ATAZANAVIR; AZITHROMYCIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; DARUNAVIR; DOXYCYCLINE; ETHAMBUTOL; FOSAMPRENAVIR; IMIPENEM; INDINAVIR; ISONIAZID; LEVOFLOXACIN; LINEZOLID; LOPINAVIR; MOXIFLOXACIN; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OFLOXACIN; RIFABUTIN; SAQUINAVIR; STREPTOMYCIN; SULFONAMIDE; TELITHROMYCIN; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG;

BRONCHIECTASIS; BRONCHOSCOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DISEASE COURSE; EPIDEMIOLOGICAL DATA; EXTRAPULMONARY TUBERCULOSIS; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LUNG INFECTION; LUNG TUBERCULOSIS; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; RISK FACTOR; THORAX RADIOGRAPHY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; MYCOBACTERIUM INFECTIONS, ATYPICAL; PRACTICE GUIDELINES AS TOPIC;

EID: 77953145981     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1255130     Document Type: Review

References (19)

1. Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne J et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009 48 1138-1151
2. Benson C, Williams P, Currier J et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003 37 1234-1243
3. Chaisson R E., Keiser P, Pierce M et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic: Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997 11 311-317
4. Griffith D E., Aksamit T, Brown-Elliott B A. et al. An Official ATS/IDSA Statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007 175 367-416
5. Jones D, Havlir D V. Nontuberculous mycobacteria in the HIV infected patient. Clin Chest Med 2002 23 665-674
6. Jones J, Hanson D, Dworkin M et al. Surveillance for AIDS-defining opportunistic illnesses, 19921997. MMWR CDC Surveill Summ 1999 48 1-22
7. Karakousis P C., Moore R D., Chaisson R E. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis 2004 4 557-565
8. Lange C G., Woolley I J., Brodt R H. Disseminated Mycobacterium avium-intracellulare Complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated? Drugs 2004 64 679-692
9. Lawn S, Bekker L, Miller R. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005 5 361-373
10. Leung K L., Yip C W., Cheung W F. et al. Development of a simple and low-cost real-time PCR method for the identification of commonly encountered mycobacteria in a high throughput laboratory. J Applied Microbiol 2009 107 1433-1439
11. Li H, Turhan V, Chokhani L et al. Identification and differentiation of clinically relevant mycobacterium species directly from acid-fast bacillus-positive culture broth. J Clin Microbiol 2009 47 3814-3820
12. Marras T K., Daley C L. A Systematic Review of the Clinical Significance of Pulmonary Mycobacterium kansasii Isolates in HIV Infection. J Acquir Immune Defic Syndr 2004 36 883-889
13. Martín-Casabona N, Bahrmand A R., Bennedsen J et al. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberculosis Lung Dis 2004 8 1186-1193
14. Mocroft A, Katlama C, Johnson A M. et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000 356 291-296
15. Phillips P, Bonner S, Gataric N et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005 41 1483-1497
16. Phillips P, Chan K, Hogg R et al. Azithromycin prophylaxis for mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program. Clin Infect Dis 2002 34 371-378
17. Rigsby M O., Curtis A M. Pulmonary disease from nontuberculous mycobacteria in patients with human immunodeficiency virus. Chest 1994 106 913-919
18. Thomson R M., Yew W-W. When and how to treat pulmonary non-tuberculous mycobacterial diseases. Respirology 2009 14 12-26
19. van Ingen J, Bendien S A., de Lange W CM et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 2009 64 502-506